

In re: Glucksmann *et al.*
Appl. No.: 09/383,745
Filed: August 26, 1999
Page 5 of 8

(g) The amino acid sequence of the mature receptor polypeptide set forth as amino acid 6 to amino acid 370 of SEQ ID NO:1; and

(h) The amino acid sequence from amino acid 6 to amino acid 370 of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. ____; the method comprising contacting a cell expressing the polypeptide with a test compound under conditions suitable for the binding of the agent to the polypeptide and detecting or measuring the formation of a complex between said polypeptide and said agent to thereby determine whether the test compound is a compound that inhibits the binding of the agent to the polypeptide, wherein the cell is derived from a tissue selected from the group consisting of: brain, spleen, lung, kidney, skeletal muscle, liver, and heart

29. The method of claim 28, wherein said polypeptide can mediate cellular signaling or a cellular response, and the formation of a complex is monitored by detecting a signaling activity or cellular response of said polypeptide in response thereto.

30. The method of claim 28, wherein said compound is an antibody.

31. The method of claim 28, wherein said agent is a ligand.

REMARKS

The foregoing amendments to the claims are fully supported in the specification and claims as originally filed. Accordingly, the foregoing amendments to the claims do not add new matter; their entry is therefore respectfully requested.

Applicants believe that the present application is now in condition for examination. If the Examiner believes, for any reason, that personal communication will expedite prosecution of this


In re: Glucksmann *et al.*
Appl. No.: 09/383,745
Filed: August 26, 1999
Page 6 of 8

application, the Examiner is invited to telephone the undersigned at the number provided.

Prompt and favorable consideration of the foregoing amendments, and entry of the same into the present application, are respectfully requested.

It is not believed that extensions of time or fees for net addition of claims are required, beyond those that may otherwise be provided for in documents accompanying this paper. However, in the event that additional extensions of time are necessary to allow consideration of this paper, such extensions are hereby petitioned under 37 CFR §1.136(a), and any fee required therefore (including fees for net addition of claims) is hereby authorized to be charged to Deposit Account No. 16-0605.

Respectfully submitted,



Kathryn L. Coulter
Registration No. 45,889

CUSTOMER NO. 000826

ALSTON & BIRD LLP

Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 420-2200
Fax Raleigh Office (919) 420-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on June 8, 2001.


Nora C. Martinez

In re: Glucksmann *et al.*
Appl. No.: 09/383,745
Filed: August 26, 1999
Page 7 of 8

Version With Markings to Show Changes Made:

Please amend claims 19 and 21 as follows:

19. A method for modulating the activity of [any of the polypeptides in claim 1,]a polypeptide comprising an amino acid selected from the group consisting of:

- (a) the amino acid sequence shown in SEQ ID NO:1;
- (b) the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. _____;
- (c) the amino acid sequence of an allelic variant of the amino acid sequence shown in SEQ ID NO:1;
- (d) the amino acid sequence of an allelic variant of the amino acid sequence encoded by the cDNA of the plasmid deposited with ATCC as Patent Deposit No. _____;
- (e) the amino acid sequence of a sequence variant of the amino acid sequence shown in SEQ ID NO:1, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes to the nucleotide sequence shown in SEQ ID NO:2 under stringent conditions;
- (f) the amino acid sequence of a sequence variant of the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. _____, wherein the sequence variant is encoded by a nucleic acid molecule that hybridizes under stringent conditions to the cDNA insert of the plasmid deposited with ATCC as Patent Deposit No. _____;
- (g) The amino acid sequence of the mature receptor polypeptide set forth as amino acid 6 to amino acid 370 of SEQ ID NO:1;
- (h) The amino acid sequence from amino acid 6 to amino acid 370 of the polypeptide encoded by the cDNA clone contained in ATCC Deposit No. _____;

the method comprising contacting [any of the polypeptides of claim 1]the polypeptide with [an agent]a compound under conditions that allow the [agent]compound to modulate the activity of

In re: Glucksmann *et al.*
Appl. No.: 09/383,745
Filed: August 26, 1999
Page 8 of 8

the polypeptide, wherein said modulation is in cells derived from tissues selected from the group consisting of brain, spleen, lung, kidney, skeletal muscle, liver, and heart.

21. The method of claim 19[20], wherein said cells are brain cells.